7th DIA Cardiac Safety Workshop in Japan

It will be a unique opportunity to learn of and discuss the current state and future directions of CV risk assessments and how to prepare for a new regulatory paradigm.

戻る Agenda

[Session 2] Non Clinical Proarrhythmic Risk Assessment

Session Chair(s)

Katsuyoshi Chiba, PhD

Senior Director and Head, Group III, Medicinal Safety Research Laboratories, R&D

Daiichi Sankyo Co., Ltd., Japan

Yasunari Kanda, PhD

Head of Division of Pharmacology

National Institute of Health Sciences, Japan

Speaker(s)

Keynote Lecture: Prediction and Quantification of Torsadogenic Potential Using Classical and New Assay Models

Atsushi Sugiyama, MD, PhD

Toho University Faculty of Medicine, Japan

Professor and Chairman, Department of Pharmacology

CiPA: Validation Efforts and Update

Gary Gintant, PhD

AbbVie Inc., United States

Research Fellow

JiCSA Update: Proarrhythmia Risk Assessment Using Human iPS Cell-derived Cardiomyocytes

Yasunari Kanda, PhD

National Institute of Health Sciences, Japan

Head of Division of Pharmacology

iSmart (investigation of in silico / in vitro model for Arrhythmogenic Risk Prediction) Update

Keiichi Asakura, PhD

Nippon Shinyaku Co., Ltd., Japan

Senior Scientist, Pharmacokinetics and Safety Assessment Department

7th DIA Cardiac Safety Workshop in Japan

[Session 2] Non Clinical Proarrhythmic Risk Assessment

Session Chair(s)

Katsuyoshi Chiba, PhD

Yasunari Kanda, PhD

Speaker(s)

Keynote Lecture: Prediction and Quantification of Torsadogenic Potential Using Classical and New Assay Models

CiPA: Validation Efforts and Update

JiCSA Update: Proarrhythmia Risk Assessment Using Human iPS Cell-derived Cardiomyocytes

iSmart (investigation of in silico / in vitro model for Arrhythmogenic Risk Prediction) Update

最新情報や機会を逃さないで